Editing Castrate-Resistant Prostate Cancer (section)

====== Docetaxel ======
* The next significant advance in the use of chemotherapy for CRPC
* '''MOA: inhibits microtubule assembly and disassembly; member of the taxane family'''
* '''Standard first-line chemotherapy for mCRPC'''
** '''Prolongs progression-free and overall survival'''
** '''Reduces pain and improves quality of life'''
** '''TAX 327'''
*** Population: 1006 mCRPC patients with no previous chemotherapy treatment and stable pain scores
*** '''Randomized''' to (all with concomitant prednisone 5 mg twice daily) '''mitoxantrone vs. docetaxel 75 mg/m2 IV every 3 weeks vs. docetaxel 30 mg/m2''' IV weekly. All patients remained on ADT
*** '''Results:'''
**** Median follow-up: 20.7 months
**** '''OS significantly improved in the every-3-week docetaxel group, not in the weekly docetaxel group''' (18.9 months every 3 weeks, 17.3 months in the weekly docetaxel group, and 16.4 months in the mitoxantrone group)
* '''Adverse events (6):'''
*# '''Myelosuppression''' (neutropenia)
*# '''Fatigue'''
*# '''Fever'''
*# '''Diarrhea, abdominal pain, constipation'''
*# '''Peripheral edema'''
*# '''Neurotoxicity'''
*# '''Hyperlacrimation'''
*# '''Nail dystrophy'''